Atila Non-Invasive Prenatal Test Kits


Description:

Noninvasive prenatal testing (NIPT) is a method to assess the risk that the fetus will be born with certain genetic abnormalities. Most common NIPT is for aneuploidy of a chromosome which is caused by the presence of an extra or missing copy of a chromosome. The test primarily looks for Down syndrome (trisomy 21), Edwards Syndrome (trisomy 18), and Patau Syndrome (trisomy 13). The test also provides fetal fraction determination.

Products:

The Atila iSAFE™ Non-Invasive Prenatal Test (NIPT) Kit screens for aneuploidy of chromosomes 21, 18, and 13 in singleton pregnancies. The kit combines Atila’s extreme multiplex PCR technology and the Digital PCR system to accurately quantify the copy numbers of chromosome 21, 18, and 13 in maternal blood cell-free DNA (cfDNA).

Key Features:
  • Highly multiplexed PCR: Enables simultaneous quantification of the chromosome 21, 18, 13, and 1, and the fetal fraction.
  • Simple procedures: Direct Digital PCR amplification on purified cfDNA
  • Simple data analysis: No complicated bioinformatics required

The Atila iSAFE™ Non-Invasive Prenatal Test (NIPT) Assay screens for aneuploidy of chromosomes 21, 18, and 13 in singleton pregnancies. The assay combines Atila’s extreme multiplex PCR technology and applies Crystal Digital PCR™ technology on the 6-color naica® system to accurately quantify the copy numbers of chromosome 21, 18, and 13 in maternal blood cell-free DNA (cfDNA).

Key Features:
  • Highly multiplexed PCR: Enables simultaneous quantification of the chromosome 21, 18, 13, and 1, and the fetal fraction.
  • Simple procedures: Direct Digital PCR amplification on purified cfDNA
  • Simple data analysis: No complicated bioinformatics required
  • The naica® system features ready-to-use digital PCR reagents and chip consumables for optimized throughput and flexible sensitivity. Easy-to-use instrument operation and intuitive software analysis enable fast time-to-results. Learn more about the naica® system workflow at naica® System Workflow | Stilla Technologies.

Gender determination and fetal fraction assay (GDFF) can simultaneously quantify cfDNA, determine fetal gender, and measure fetal fraction for male fetus in the maternal blood cfDNA. The assay can be performed first and separately for gender determination and fetal fraction determination. The quantification derived from this assay can be used for NIPT assay.

Key Features:
  • Highly multiplexed PCR: Enables simultaneous quantification of chromosome Y and a reference chromosome.
  • Simple procedures: Direct Digital PCR amplification on purified cfDNA
  • Simple data analysis: Simple readout. No complicated bioinformatics required

Genomic DNA contamination assay tests and quantifies large genomic DNA fragments in the purified cell free DNA. The result is used to assess the quality of the purified cfDNA.

Key Features:
  • Simple procedures: Direct Digital PCR amplification on purified cfDNA
  • Simple data analysis: Simple readout. No complicated bioinformatics required

Technical Specs:

  • Sample Types: purified maternal cfDNA
  • Assay Time: 3 hours
  • Hands-On Time: 30 minutes
  • System Compatibility: Digital PCR System
  • Method: Multiplex Digital PCR

*Order Information:

Cat. No.   

Description                                                                                         

 Size

NIPT-100Q iSAFE™ Non-Invasive Prenatal Test Kit For Trisomy 21, Trisomy 18, Trisomy 13 Detection, Fetal Fraction, and Gender Determination 100 reactions
NIPT-100 iSAFE™ Non-Invasive Prenatal Test Assay For Trisomy 21, Trisomy 18, Trisomy 13 Detection, Fetal Fraction, and Gender Determination on the naica® system (Stilla Technologies) 100 reactions
NIPT-Y-100Q NIPT Gender Determination and Fetal Fraction Assay 100 reactions
NIPT-GS-100Q NIPT Genomic DNA Contamination Assay 100 reactions

*  These products are for research use only.

Contact us for a quote or any question about our products